SUPN Supernus Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-09 11:25
Why SUPN matters now
Supernus Pharmaceuticals, Inc. (SUPN) is a US stock in Healthcare. The latest InvestLog snapshot shows $48.67 with -3.51% on the session and $2.82B in market capitalization; recent performance reads 1-month -6.80% and YTD -10.70%.
The latest financial table shown here is Q1 2026, with revenue of $207.7M, net income of $-2.3M, and EPS of $-0.04. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 3.2%.
The latest indexable market news headline is "Strength Seen in Supernus (SUPN): Can Its 5.2% Jump Turn into More Strength?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $65.00; recent insider activity includes Bhatt Padmanabh P. filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.38
P/S
3.32
EV/EBITDA
47.00
DCF Value
$117.88
FCF Yield
3.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.4%
Operating Margin
-5.4%
Net Margin
-3.7%
ROE
-2.7%
ROA
-1.9%
ROIC
-2.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $207.7M | $-2.3M | $-0.04 |
| Q4 2025 | $211.6M | $-4.1M | $-0.07 |
| FY 2025 | $719.0M | $-38.5M | $-0.68 |
| Q3 2025 | $192.1M | $-45.1M | $-0.80 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$65.00
Target (Median)
$65.00
Target Range
$65.00 - $65.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
0.54
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.